Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/3/jgs16697-sup-0001-Supinfo.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/2/jgs16697_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/1/jgs16697.pd

Study protocol: The Adherence and Intensification of Medications (AIM) study - a cluster randomized controlled effectiveness study

Abstract Background Many patients with diabetes have poor blood pressure (BP) control. Pharmacological therapy is the cornerstone of effective BP treatment, yet there are high rates both of poor medication adherence and failure to intensify medications. Successful medication management requires an effective partnership between providers who initiate and increase doses of effective medications and patients who adhere to the regimen. Methods In this cluster-randomized controlled effectiveness study, primary care teams within sites were randomized to a program led by a clinical pharmacist trained in motivational interviewing-based behavioral counseling approaches and authorized to make BP medication changes or to usual care. This study involved the collection of data during a 14-month intervention period in three Department of Veterans Affairs facilities and two Kaiser Permanente Northern California facilities. The clinical pharmacist was supported by clinical information systems that enabled proactive identification of, and outreach to, eligible patients identified on the basis of poor BP control and either medication refill gaps or lack of recent medication intensification. The primary outcome is the relative change in systolic blood pressure (SBP) measurements over time. Secondary outcomes are changes in Hemoglobin A1c, low-density lipoprotein cholesterol (LDL), medication adherence determined from pharmacy refill data, and medication intensification rates. Discussion Integration of the three intervention elements - proactive identification, adherence counseling and medication intensification - is essential to achieve optimal levels of control for high-risk patients. Testing the effectiveness of this intervention at the team level allows us to study the program as it would typically be implemented within a clinic setting, including how it integrates with other elements of care. Trial Registration The ClinicalTrials.gov registration number is NCT00495794.http://deepblue.lib.umich.edu/bitstream/2027.42/78258/1/1745-6215-11-95.xmlhttp://deepblue.lib.umich.edu/bitstream/2027.42/78258/2/1745-6215-11-95.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/78258/3/1745-6215-11-95-S1.DOCPeer Reviewe

Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139955/1/hesr12788-sup-0001-AppendixSA1.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/139955/2/hesr12788_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/139955/3/hesr12788.pd

Michigan Diabetes Outreach Networks: A Public Health Approach to Strengthening Diabetes Care

This study describes a statewide public health approach to strengthen diabetes care; evaluates diabetes-related processes of care for individuals enrolled in the Michigan Diabetes Outreach Network (MDON) program; and, examines MDON in the context of priorities for diabetes care and public health policy. Organizational information was obtained through semi-structured interviews. Program outcomes are examined using data from client intake and follow-up assessment forms. We report percentages and mean values overall and across networks. Logistic regression is used to identify factors associated with clients receiving recommended diabetes care. Within two years, five of the networks recruited 125 providers and collected information on over 8,000 individuals with diabetes. The percentage of enrollees with a glycosylated hemoglobin measure, eye exam, and dietician visit is greater at follow-up than at intake and an intake “referral” is strongly associated with clients being treated for high blood pressure at follow-up. The MDON model is a promising public health approach for improving diabetes care but it is necessary to identify program elements that are most effective.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44940/1/10900_2004_Article_227488.pd

Focus and features of prescribing indications spanning multiple chronic conditions in older adults: A narrative review

Background: Inappropriate prescribing is frequent in older adults and associated with adverse outcomes. Prescribing indications aim to optimize prescribing, but little is known about the focus and features of prescribing indications for the most common chronic conditions in older adults. Understanding the conditions, medications, and issues addressed (e.g., patient perspective, drug-disease interaction, adverse drug event) in current prescribing indications may help to identify missing indications and develop standardized measures to improve prescribing quality. Methods: We searched Ovid/MEDLINE and EMBASE for articles published between 2015 and 2020 reporting prescribing indications for older adults. Prescribing indication included 1) prescribing “criteria,” or statements that guide prescribing action, and 2) prescribing “measures,” or prescribing actions observed in a population. We categorized their focus by conditions, medications and issues addressed, as well as level of evidence provided. Results: Among 16 sets of prescribing indications, we identified 748 criteria and 47 measures. The most common addressed medications were antihypertensives, analgesics/antirheumatics, and antiplatelets/anticoagulants. The most frequently addressed issues were drug-disease interaction, adverse drug event, administration, better therapeutic alternative, and (co-)prescription omission (20.8–36.1%). Age/functioning, drug-drug interaction, monitoring, and efficacy/ safety ratio were found in only 9.9–16.5% of indications. Indications rarely focused on the patient perspective or issues with multiple providers. Conclusion: Most prescribing indications for chronic conditions in older patients are criteria rather than measures. Indications accounting for patient perspective and multiple providers are limited. The gaps identified in this review may help improve the development of prescribing measures for older adults and ultimately improve quality of care

First Things First: Difficulty with Current Medications is Associated with Patient Willingness to Add New Ones

Background: Inadequate BP control remains prevalent. One proposed explanation is 'clinical inertia,' often defined as the failure by providers to initiate or intensify medication therapy when otherwise appropriate. However, patients could contribute to clinical inertia by signaling an unwillingness to consider medication intensification. Abstract: Objective: To explore co-variates of patient attitudes likely to predict patients' willingness to intensify (WTI) their medication regimen. Abstract: Methods: A cross-sectional survey was conducted in nine Midwestern US Veterans' Administration medical facilities as part of a prospective cohort study of clinical inertia in hypertension treatment. 1062 patients with diabetes mellitus, identified as having BP ≥140/90 mmHg, were surveyed. Primary outcome was participants' indicated WTI BP medications if their provider noted elevated BP levels. Potential co-variates assessed included BP control (actual and perceived), perceived importance of BP control, BP management self-efficacy, competing demands, medication factors (adherence and management issues), trust in provider, and sociodemographic factors. Abstract: Results: While 64% of participants reported complete WTI BP medications, 36% of participants expressed at least some unwillingness. In ordered logistic regression analysis, WTI was negatively associated with medication concerns, particularly concern about adverse effects (odds ratio [OR] 0.49; 95% CI 0.42, 0.59) and adherence or management problems (OR 0.72; 95% CI 0.57, 0.91), and positively associated with perceived dependence of health on BP medications (OR 1.50; 95% CI 1.26, 1.79) and trust in provider (OR 1.30; 95% CI 1.10, 1.54). Importance of BP control had a weaker, nonsignificant association with WTI (OR 1.17; 95% CI 0.99, 1.40). Competing demands, current BP control, current number of medications prescribed, and self-efficacy were not associated with WTI medications. Abstract: Conclusions: Patients' willingness to consider intensification of BP medications appears primarily determined by how well patients are managing their current medications, rather than patients' perceived importance of BP control, their self-efficacy, or their prioritization of BP control versus other health demands. Greater attention to patients' pre-existing medication issues may improve providers' ability to intensify BP medication therapy when medically appropriate while simultaneously improving patient satisfaction with care.

Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study.

BACKGROUND The COVID-19 pandemic required a change in outpatient care delivery models, including shifting from in-person to virtual visits, which may have impacted care of vulnerable patients. OBJECTIVE To describe the changes in management, control, and outcomes in older people with type 2 diabetes (T2D) associated with the shift from in-person to virtual visits. DESIGN AND PARTICIPANTS In veterans aged ≥ 65 years with T2D, we assessed the rates of visits (in person, virtual), A1c measurements, antidiabetic deintensification/intensification, ER visits and hospitalizations (for hypoglycemia, hyperglycemia, other causes), and A1c level, in March 2020 and April-November 2020 (pandemic period). We used negative binomial regression to assess change over time (reference: pre-pandemic period, July 2018 to February 2020), by baseline Charlson Comorbidity Index (CCI; > 2 vs. <= 2) and A1c level. KEY RESULTS Among 740,602 veterans (mean age 74.2 [SD 6.6] years), there were 55% (95% CI 52-58%) fewer in-person visits, 821% (95% CI 793-856%) more virtual visits, 6% (95% CI 1-11%) fewer A1c measurements, and 14% (95% CI 10-17%) more treatment intensification during the pandemic, relative to baseline. Patients with CCI > 2 had a 14% (95% CI 12-16%) smaller relative increase in virtual visits than those with CCI <= 2. We observed a seasonality of A1c level and treatment modification, but no association of either with the pandemic. After a decrease at the beginning of the pandemic, there was a rebound in other-cause (but not hypo- and hyperglycemia-related) ER visits and hospitalizations from June to November 2020. CONCLUSION Despite a shift to virtual visits and a decrease in A1c measurement during the pandemic, we observed no association with A1c level or short-term T2D-related outcomes, providing some reassurance about the adequacy of virtual visits. Further studies should assess the longer-term effects of shifting to virtual visits in different populations to help individualize care, improve efficiency, and maintain appropriate care while reducing overuse

Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/3/jgs16697-sup-0001-Supinfo.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/2/jgs16697_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163374/1/jgs16697.pd